Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):513–518. doi: 10.1038/sj.bjc.6690386

Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study

J Nuutinen 1,2, H Minn 1,2, J Bergman 2, M Haaparanta 2, U Ruotsalainen 2, H Laine 2, J Knuuti 2
PMCID: PMC2362346  PMID: 10408861

Abstract

Increased use of glucose through glycolysis is characteristic for neoplastic growth while the significance of serum-free fatty acids for regulation of energy metabolism in cancer is poorly understood. We studied whether serum-free fatty acids (FFA) interfere with glycolytic metabolism of lymphoproliferative neoplasms as assessed with 2-F18-fluoro-2-deoxy-D-glucose ([F18]FDG) and positron emission tomography (PET). Twelve patients with newly diagnosed non-Hodgkin's lymphoma (n = 9) or Hodgkin's disease (n = 3) participated in this study before start of oncologic treatment. Each patient underwent two [F18]FDG PET studies within 1 week after overnight fast: once during high fasting serum FFA concentrations and once after reduction of serum FFA by administration of acipimox. Acipimox is a nicotinic acid derivative that inhibits lipolysis in peripheral tissues and induces a striking reduction in circulating FFA concentration. In all cases, dynamic PET imaging over the tumour area was performed for 60 min after injection of [F18]FDG. Both graphical analysis (rMRFDG) and single scan approach (SUV) were used to compare tumour uptake of [F18]FDG under high fasting FFA concentrations and after pharmacologically decreased FFA concentrations. Serum FFA concentrations were reduced significantly from 0.92 ± 0.42 mmol l−1 at baseline to 0.26 ± 0.31 mmol l−1 after acipimox administration (P = 0.0003). Plasma glucose, serum insulin and lactate concentrations were similar during both approaches. The retention of glucose analogue [F18]FDG in tumour was similar between baseline and acipimox studies. Median rMRFDG of a total of 12 involved lymph nodes in 12 patients was 21.9 μmol 100 g−1 min−1 (range 8.7–82.5) at baseline and 20.1 μmol 100 g−1 min−1 (range 10.7–81.7) after acipimox. The respective values for median SUV were 7.8 (range 3.6–18.6) and 6.0 (range 4.1–20.2). As expected, [F18]FDG uptake in myocardium was clearly enhanced by acipimox due to reduction of circulating FFAs. In conclusion, blood fatty acids appear to have minor significance for [F18]FDG uptake in lymphoma. This suggests that glucose utilization is uncoupled of FFA metabolism and indicates that glucose-free fatty acid cycle does not operate in lymphomatous tissue. Glucose appears to be the preferred substrate for energy metabolism in tumours, in spite of the high supply of FFAs in the fasting state. Although acipimox and other anti-lipolytic drugs have potential for treatment of catabolic state induced by cancer, they are not likely to interfere with tumour energy metabolism which is fuelled by glucose. © 1999 Cancer Research Campaign

Keywords: lymphoma, glucose metabolism, FFA, FDG PET

Full Text

The Full Text of this article is available as a PDF (107.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993 Sep 30;329(14):987–994. doi: 10.1056/NEJM199309303291402. [DOI] [PubMed] [Google Scholar]
  2. Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971 Nov;31(11):1860–1861. [PubMed] [Google Scholar]
  3. Cederbaum A. I., Rubin E. Fatty acid oxidation, substrate shuttles, and activity of the citric acid cycle in hepatocellular carcinomas of varying differentiation. Cancer Res. 1976 Sep;36(9 PT1):2980–2987. [PubMed] [Google Scholar]
  4. Conti P. S., Lilien D. L., Hawley K., Keppler J., Grafton S. T., Bading J. R. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol. 1996 Aug;23(6):717–735. doi: 10.1016/0969-8051(96)00074-1. [DOI] [PubMed] [Google Scholar]
  5. Gullino P. M., Grantham F. H., Courtney A. H. Glucose consumption by transplanted tumors in vivo. Cancer Res. 1967 Jun;27(6):1031–1040. [PubMed] [Google Scholar]
  6. Hamacher K., Coenen H. H., Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986 Feb;27(2):235–238. [PubMed] [Google Scholar]
  7. Kern K. A., Norton J. A. Cancer cachexia. JPEN J Parenter Enteral Nutr. 1988 May-Jun;12(3):286–298. doi: 10.1177/0148607188012003286. [DOI] [PubMed] [Google Scholar]
  8. Knuuti M. J., Mäki M., Yki-Järvinen H., Voipio-Pulkki L. M., Härkönen R., Haaparanta M., Nuutila P. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol. 1995 Jul;27(7):1359–1367. doi: 10.1006/jmcc.1995.0129. [DOI] [PubMed] [Google Scholar]
  9. Knuuti M. J., Nuutila P., Ruotsalainen U., Saraste M., Härkönen R., Ahonen A., Teräs M., Haaparanta M., Wegelius U., Haapanen A. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med. 1992 Jul;33(7):1255–1262. [PubMed] [Google Scholar]
  10. Kuzuya H., Blix P. M., Horwitz D. L., Steiner D. F., Rubenstein A. H. Determination of free and total insulin and C-peptide in insulin-treated diabetics. Diabetes. 1977 Jan;26(1):22–29. doi: 10.2337/diab.26.1.22. [DOI] [PubMed] [Google Scholar]
  11. Lapela M., Leskinen S., Minn H. R., Lindholm P., Klemi P. J., Söderström K. O., Bergman J., Haaparanta M., Ruotsalainen U., Solin O. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood. 1995 Nov 1;86(9):3522–3527. [PubMed] [Google Scholar]
  12. Lavezzari M., Milanesi G., Oggioni E., Pamparana F. Results of a phase IV study carried out with acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia. J Int Med Res. 1989 Jul-Aug;17(4):373–380. doi: 10.1177/030006058901700411. [DOI] [PubMed] [Google Scholar]
  13. Marbach E. P., Weil M. H. Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem. 1967 Apr;13(4):314–325. [PubMed] [Google Scholar]
  14. Miles J., Glasscock R., Aikens J., Gerich J., Haymond M. A microfluorometric method for the determination of free fatty acids in plasma. J Lipid Res. 1983 Jan;24(1):96–99. [PubMed] [Google Scholar]
  15. Minn H., Nuutila P., Lindholm P., Ruotsalainen U., Bergman J., Teräs M., Knuuti M. J. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer. 1994 Mar 1;73(5):1490–1498. doi: 10.1002/1097-0142(19940301)73:5<1490::aid-cncr2820730528>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  16. Minn H., Zasadny K. R., Quint L. E., Wahl R. L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995 Jul;196(1):167–173. doi: 10.1148/radiology.196.1.7784562. [DOI] [PubMed] [Google Scholar]
  17. Mulligan H. D., Beck S. A., Tisdale M. J. Lipid metabolism in cancer cachexia. Br J Cancer. 1992 Jul;66(1):57–61. doi: 10.1038/bjc.1992.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nariai T., DeGeorge J. J., Greig N. H., Genka S., Rapoport S. I., Purdon A. D. Differences in rates of incorporation of intravenously injected radiolabeled fatty acids into phospholipids of intracerebrally implanted tumor and brain in awake rats. Clin Exp Metastasis. 1994 May;12(3):213–225. doi: 10.1007/BF01753889. [DOI] [PubMed] [Google Scholar]
  19. Noguchi M., Rose D. P., Earashi M., Miyazaki I. The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology. 1995 Jul-Aug;52(4):265–271. doi: 10.1159/000227471. [DOI] [PubMed] [Google Scholar]
  20. Norton J. A., Burt M. E., Brennan M. F. In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer. 1980 Jun 15;45(12):2934–2939. doi: 10.1002/1097-0142(19800615)45:12<2934::aid-cncr2820451206>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  21. Nuutila P., Knuuti M. J., Raitakari M., Ruotsalainen U., Teräs M., Voipio-Pulkki L. M., Haaparanta M., Solin O., Wegelius U., Yki-Järvinen H. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted humans. Am J Physiol. 1994 Dec;267(6 Pt 1):E941–E946. doi: 10.1152/ajpendo.1994.267.6.E941. [DOI] [PubMed] [Google Scholar]
  22. Nuutila P., Koivisto V. A., Knuuti J., Ruotsalainen U., Teräs M., Haaparanta M., Bergman J., Solin O., Voipio-Pulkki L. M., Wegelius U. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest. 1992 Jun;89(6):1767–1774. doi: 10.1172/JCI115780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Obeid O. A., Emery P. W. Effect of acute acipimox administration on the rates of lipid and glycogen synthesis in cachectic tumor-bearing rats. Nutr Cancer. 1997;28(1):100–106. doi: 10.1080/01635589709514559. [DOI] [PubMed] [Google Scholar]
  24. Patlak C. S., Blasberg R. G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985 Dec;5(4):584–590. doi: 10.1038/jcbfm.1985.87. [DOI] [PubMed] [Google Scholar]
  25. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987 Mar;28(3):288–292. [PubMed] [Google Scholar]
  26. Phelps M. E., Huang S. C., Hoffman E. J., Selin C., Sokoloff L., Kuhl D. E. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979 Nov;6(5):371–388. doi: 10.1002/ana.410060502. [DOI] [PubMed] [Google Scholar]
  27. RANDLE P. J., GARLAND P. B., HALES C. N., NEWSHOLME E. A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963 Apr 13;1(7285):785–789. doi: 10.1016/s0140-6736(63)91500-9. [DOI] [PubMed] [Google Scholar]
  28. Randle P. J., Newsholme E. A., Garland P. B. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem J. 1964 Dec;93(3):652–665. doi: 10.1042/bj0930652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Ratib O., Phelps M. E., Huang S. C., Henze E., Selin C. E., Schelbert H. R. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism. J Nucl Med. 1982 Jul;23(7):577–586. [PubMed] [Google Scholar]
  30. Spence A. M., Muzi M., Graham M. M., O'Sullivan F., Krohn K. A., Link J. M., Lewellen T. K., Lewellen B., Freeman S. D., Berger M. S. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med. 1998 Mar;39(3):440–448. [PubMed] [Google Scholar]
  31. Stansfeld A. G., Diebold J., Noel H., Kapanci Y., Rilke F., Kelényi G., Sundstrom C., Lennert K., van Unnik J. A., Mioduszewska O. Updated Kiel classification for lymphomas. Lancet. 1988 Feb 6;1(8580):292–293. doi: 10.1016/s0140-6736(88)90367-4. [DOI] [PubMed] [Google Scholar]
  32. Tayek J. A. A review of cancer cachexia and abnormal glucose metabolism in humans with cancer. J Am Coll Nutr. 1992 Aug;11(4):445–456. doi: 10.1080/07315724.1992.10718249. [DOI] [PubMed] [Google Scholar]
  33. Thiébaud D., DeFronzo R. A., Jacot E., Golay A., Acheson K., Maeder E., Jéquier E., Felber J. P. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 1982 Nov;31(11):1128–1136. doi: 10.1016/0026-0495(82)90163-9. [DOI] [PubMed] [Google Scholar]
  34. Toomey D., Redmond H. P., Bouchier-Hayes D. Mechanisms mediating cancer cachexia. Cancer. 1995 Dec 15;76(12):2418–2426. doi: 10.1002/1097-0142(19951215)76:12<2418::aid-cncr2820761204>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  35. Wahl R. L., Zasadny K., Helvie M., Hutchins G. D., Weber B., Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993 Nov;11(11):2101–2111. doi: 10.1200/JCO.1993.11.11.2101. [DOI] [PubMed] [Google Scholar]
  36. Woodard H. Q., Bigler R. E., Freed B. Letter: Expression of tissue isotope distribution. J Nucl Med. 1975 Oct;16(10):958–959. [PubMed] [Google Scholar]
  37. Zasadny K. R., Wahl R. L. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993 Dec;189(3):847–850. doi: 10.1148/radiology.189.3.8234714. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES